MindMaze Therapeutics Holding (RLFTF)

[Inelgr]

The reason they pulled the study is not necessarily because their version of VIP didn't work for Covid (although, I haven't seen the press releases from them regarding successes like we've seen with Aviptadil)...it's because they had a poorly designed study. Sounds like they don't have the rock stars working for them like Relief/NeuroRX have.

"Based on feedback from the FDA, the company determined that the 70 patients targeted for enrollment in each of the VANGARD trial’s treatment arms would be insufficient in size to adequately evaluate mortality and that at least one additional clinical trial with a mortality endpoint, would be required."

The article goes on to state that they will simply refocus their drug

"The ongoing Phase 2b trial of pemziviptadil in patients with pulmonary arterial hypertension (PAH) is expected to resume enrollment after a pause related to COVID-19 pandemic and re-prioritization of drug supply to the VANGARD trial. To date, around 1/3rd of the patients targeted for enrollment have completed the initial 16 week protocol. Results are expected in 2H 2021."

.